Voyager Therapeutics (NASDAQ:VYGR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
According to Zacks, “Voyager Therapeutics, Inc. is a gene therapy company. It focuses on the development of treatments for patients suffering from severe diseases of the central nervous system. Its pipeline includes VY-AADC01, which is in Phase 1b clinical trials for treatment of Parkinson’s disease and preclinical programs comprise VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis, VY-FXN01 for Friedreich ataxia and VY-HTT01 for Huntington’s disease as well as VY-SMN101 for neuromuscular disease. Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
A number of other equities analysts have also recently weighed in on the stock. Morgan Stanley began coverage on shares of Voyager Therapeutics in a research report on Friday, February 2nd. They set an “overweight” rating for the company. BidaskClub cut shares of Voyager Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Friday, February 2nd. Canaccord Genuity restated a “buy” rating and set a $26.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, January 23rd. BTIG Research began coverage on shares of Voyager Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $32.00 price objective for the company. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $28.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, November 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $26.90.
Voyager Therapeutics (VYGR) traded up $0.19 during trading hours on Tuesday, reaching $19.36. 169,900 shares of the company’s stock were exchanged, compared to its average volume of 304,175. The firm has a market capitalization of $608.86, a PE ratio of -6.82 and a beta of 4.04. Voyager Therapeutics has a 52 week low of $8.10 and a 52 week high of $25.99.
In other news, insider Bernard Ravina sold 5,490 shares of the stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $13.63, for a total value of $74,828.70. Following the completion of the sale, the insider now directly owns 10,983 shares in the company, valued at $149,698.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 11,571 shares of company stock valued at $179,067 over the last quarter. Company insiders own 8.00% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of VYGR. BlackRock Inc. raised its position in shares of Voyager Therapeutics by 73.9% in the fourth quarter. BlackRock Inc. now owns 1,210,763 shares of the company’s stock valued at $20,099,000 after buying an additional 514,345 shares during the last quarter. Farallon Capital Management LLC raised its position in shares of Voyager Therapeutics by 290.5% in the fourth quarter. Farallon Capital Management LLC now owns 654,812 shares of the company’s stock valued at $10,870,000 after buying an additional 487,147 shares during the last quarter. AXA acquired a new stake in shares of Voyager Therapeutics in the fourth quarter valued at about $5,591,000. Wells Fargo & Company MN raised its position in shares of Voyager Therapeutics by 312.8% in the third quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock valued at $7,766,000 after buying an additional 285,806 shares during the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Voyager Therapeutics in the fourth quarter valued at about $4,579,000. Institutional investors and hedge funds own 70.52% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.